Aprea Therapeutics (APRE)

• Market cap: $4.13M
• 1 day: -22.78%
• 5 days: -31.05%
• 1 month: -35.9%
• 3 months: -59.31%
• 6 months: -66.48%
• Year to date: -30.83%
• 1 year: -84.1%
• 5 years: -99.47%
• 10 years: -99.86%
• Sector: Healthcare
• Industry: Biotechnology

About: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Employees: 8